RxDown
Medication withdrawal, explained properly
Plain-language education grounded in the Maudsley Deprescribing Guidelines, the Ashton Manual, and peer-reviewed research — every claim cited, every article dated. Education, not medical advice: work with your prescriber.
No guides match that search. Try a medication name, symptom, or broader topic.
Start Here & Tapering Fundamentals
5 articles
Holding, Slowing, or Reinstating During a Medication Taper: Why the Drug Class Matters
A class-specific guide to holding, slowing, and reinstating after withdrawal symptoms, replacing unsafe one-size-fits-all advice.
Evidence reviewed through: Aug 19, 2026 Start Here & Tapering FundamentalsI Stopped My Medication and Feel Unwell—What Information Should I Gather Now?
A calm first-response guide for symptoms after stopping a medication: emergency warning signs, the information a clinician needs, and why repeated…
Evidence reviewed through: Aug 18, 2026 Start Here & Tapering FundamentalsMissed Dose or Withdrawal? How Timing, Half-Life, and Formulation Change the Pattern
How to interpret symptoms after a late or missed medication dose without assuming that timing alone proves withdrawal.
Evidence reviewed through: Aug 18, 2026 Start Here & Tapering FundamentalsHyperbolic Tapering: Why Proportional Cuts Beat Fixed Ones
Hyperbolic tapering reduces a drug by a proportion of the current dose, so each cut shrinks as you go lower—matching receptor occupancy and easing withdrawal.
Jul 2, 2026 Start Here & Tapering FundamentalsWhen and How to Start Tapering: Methods, Symptoms, and What Fits You
How to judge whether now is the right time to reduce a medication, the main tapering methods compared, the symptoms to expect, and how to match an approach to your drug and situation.
Jul 2, 2026Antidepressants
16 articles
Bupropion (Wellbutrin) Withdrawal: How Its Discontinuation Profile Differs
Evidence-based answers about bupropion dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsDuloxetine (Cymbalta) Withdrawal: Delayed-Release Capsules, Symptoms, and Tapering Questions
Evidence-based answers about duloxetine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsEscitalopram (Lexapro) Withdrawal: What to Expect After a Dose Reduction
Evidence-based answers about escitalopram dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsFluoxetine (Prozac) Withdrawal: Delayed Symptoms and the “Prozac Bridge” Question
Evidence-based answers about fluoxetine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsMirtazapine (Remeron) Withdrawal: Sleep, Appetite, and Nausea
Evidence-based answers about mirtazapine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsParoxetine (Paxil) Withdrawal: Why Symptoms Can Start Quickly
Evidence-based answers about paroxetine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsSertraline (Zoloft) Withdrawal: Symptoms, Timeline, and Tapering Questions
Evidence-based answers about sertraline dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsVenlafaxine (Effexor XR) Withdrawal: Missed Doses, Timeline, and Formulation Issues
Evidence-based answers about venlafaxine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsCitalopram (Celexa) Withdrawal and Tapering Questions
Evidence-based answers about citalopram dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsCross-Tapering Antidepressants vs Tapering to Stop: Different Goals, Different Risks
Why switching between antidepressants and stopping treatment are different clinical projects, with different interaction, withdrawal, and relapse risks.
Evidence reviewed through: Aug 18, 2026 AntidepressantsDesvenlafaxine (Pristiq) Withdrawal: Symptoms and Extended-Release Formulations
Evidence-based answers about desvenlafaxine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsTrazodone Withdrawal: Sleep Rebound, Nausea, and Mood Symptoms
Evidence-based answers about trazodone dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsVortioxetine (Trintellix) Discontinuation: What Trials Show and What Real-World Evidence Lacks
Evidence-based answers about vortioxetine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 AntidepressantsPediatric and Adolescent Antidepressant Discontinuation: What Is Known and What Is Not
A specialist-review guide to antidepressant discontinuation in children and adolescents, including limited evidence, developmental context, relapse…
Evidence reviewed through: Aug 18, 2026 AntidepressantsAntidepressant Withdrawal Timeline: Symptoms & Duration
Antidepressant withdrawal often starts 1–4 days after a dose cut, causing flu-like, sensory, and sleep symptoms. Most ease within weeks, but some last longer.
Jul 2, 2026 AntidepressantsAntidepressant withdrawal vs relapse: how to tell
Withdrawal starts days after a dose cut and eases within days of reinstatement; relapse builds over weeks and looks like your original illness. How to tell.
Jul 2, 2026Benzodiazepines
11 articles
Benzodiazepine Tapering and the Ashton Manual: What Still Helps and What 2025 Guidance Changes
A corrected comparison of the Ashton Manual, ASAM 2025, and NICE, including accurate pace wording and symptom-responsive adjustment.
Evidence reviewed through: Aug 19, 2026 BenzodiazepinesAlprazolam (Xanax) Withdrawal: Interdose Symptoms, Risks, and Tapering Questions
Evidence-based answers about alprazolam dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 BenzodiazepinesBenzodiazepine Taper Symptoms: Hold, Slow Down, or Return to the Previous Dose?
What current guidelines say about symptoms after a benzodiazepine reduction, including when to pause, make a smaller reduction, slow down, or consider the previous dose.
Evidence reviewed through: Aug 19, 2026 BenzodiazepinesClonazepam (Klonopin) Withdrawal: Timeline, Long Half-Life, and Tapering Questions
Evidence-based answers about clonazepam dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 19, 2026 BenzodiazepinesDiazepam (Valium) Tapering: Long Half-Life, Accumulation, and Substitution Limits
Evidence-based answers about diazepam dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 BenzodiazepinesDirect Benzodiazepine Taper vs Diazepam Substitution: What the 2025 Guideline Says
A comparison of direct benzodiazepine tapering and transition to diazepam or another longer-acting medication, including the limits of equivalence tables.
Evidence reviewed through: Aug 18, 2026 BenzodiazepinesLorazepam (Ativan) Withdrawal: Symptoms, Timing, and Safety Questions
Evidence-based answers about lorazepam dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 BenzodiazepinesAlcohol, Opioids, and Other Sedatives During a Benzodiazepine Taper
Why alcohol, opioids, gabapentinoids, Z-drugs, and other sedatives change benzodiazepine taper safety—and why abrupt alcohol cessation may itself be…
Evidence reviewed through: Aug 18, 2026 BenzodiazepinesBenzodiazepine Dose Equivalence: Why Conversion Tables Are Only Estimates
How benzodiazepine equivalence tables are constructed, why values differ, and why a calculated diazepam equivalent is not a personal conversion dose.
Evidence reviewed through: Aug 18, 2026 BenzodiazepinesBenzodiazepines in Older Adults: Falls, Cognition, Polypharmacy, and Tapering Decisions
How to balance fall, cognitive, interaction, and withdrawal risks when considering benzodiazepine reduction in older adults.
Evidence reviewed through: Aug 18, 2026 BenzodiazepinesInterdose Withdrawal: Why Symptoms Can Appear Before the Next Dose
What “interdose withdrawal” means, which patterns support it, what can mimic it, and why changing dose frequency without a plan can create new risks.
Evidence reviewed through: Aug 18, 2026Sleep Medications
17 articles
CBT-I During a Sleeping-Pill or Benzodiazepine Taper: What the Evidence Supports
How cognitive behavioral therapy for insomnia can support sleep-medication or benzodiazepine reduction without promising that it prevents every withdrawal…
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsCBT-I During Pregnancy and Postpartum: Evidence, Adaptations, and Limits
What randomized trials show about CBT-I during pregnancy and after birth, including adaptations, mood outcomes, infant-related sleep disruption, and safety limits.
Evidence reviewed through: Aug 19, 2026 Sleep MedicationsCBT-I for Adolescents: Evidence, Family Support, and Digital Programs
An evidence-based guide to CBT-I for adolescents, including circadian timing, school schedules, family involvement, digital programs, mood, and safety.
Evidence reviewed through: Aug 19, 2026 Sleep MedicationsCBT-I vs Sleep Hygiene: Why Advice Alone Is Not the Same Treatment
A clear comparison of cognitive behavioral therapy for insomnia and sleep hygiene, including active components, evidence, safety, and when advice alone is insufficient.
Evidence reviewed through: Aug 19, 2026 Sleep MedicationsSleep Restriction and Sleep Compression in CBT-I: Safety, Adaptations, and Clinical Oversight
How sleep-window therapy and sleep compression work in CBT-I, why the term sleep restriction can mislead, and when safety adaptations or clinician oversight are needed.
Evidence reviewed through: Aug 19, 2026 Sleep MedicationsZolpidem (Ambien) Withdrawal and Rebound Insomnia
Evidence-based answers about zolpidem dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsBreast Cancer Survivorship, Endocrine Therapy, Hot Flashes, and Insomnia
An evidence-based guide to insomnia in breast cancer survivorship, integrating endocrine therapy, vasomotor symptoms, pain, mood, sleep disorders, and…
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsCancer-Related Insomnia and Sleep Medications: Interactions, Delirium, Falls, and Tapering Questions
A safety-first guide to sleep medications during cancer treatment and survivorship, covering interactions, delirium, falls, respiratory risk, long-term…
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsCBT-I for Cancer Survivors: Evidence, Delivery Options, and Who May Need More
A research-grounded guide to cognitive behavioral therapy for insomnia in cancer survivors, including components, delivery formats, expected benefits,…
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsInsomnia After Cancer Treatment: Why It Persists and How It Is Assessed
An evidence-based overview of persistent insomnia during and after cancer treatment, including contributors, validated assessment, sleep-disorder…
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsEszopiclone (Lunesta) Withdrawal and Rebound Insomnia
Evidence-based answers about eszopiclone dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsZaleplon (Sonata) Withdrawal: Short Half-Life and Rebound Sleep Problems
Evidence-based answers about zaleplon dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsZopiclone Withdrawal: Dependence and Tapering Questions
Evidence-based answers about zopiclone dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Sleep MedicationsKnow Your Medication: Benzodiazepines vs Z-Drugs vs DORAs
A plain-language guide to identifying your sleep or anxiety medication's class — benzodiazepine, Z-drug, DORA, and the rest — and why the class decides how you should stop.
Jul 2, 2026 Sleep MedicationsSleeping Pills vs. Sedatives: Are They the Same Thing?
Sleeping pill, sedative, tranquilizer, hypnotic, anxiolytic — the labels overlap and often describe the same drug. Here's what really separates them and why it matters when you stop.
Jul 2, 2026 Sleep MedicationsStopping DORA Sleep Meds: Quviviq, Dayvigo, Belsomra
DORA sleep drugs (daridorexant, lemborexant, suvorexant) block wake signals, not GABA. Trials show no rebound insomnia or withdrawal when they're stopped.
Jul 2, 2026 Sleep MedicationsZ-Drugs (Ambien, Lunesta): Dependence and Safe Reduction
Z-drugs like zolpidem and zopiclone can cause tolerance, dependence, and rebound insomnia. Learn evidence-based, prescriber-supervised ways to reduce them.
Jul 2, 2026Sleep & CBT-I
9 articles
CBT-I for Bipolar Disorder: Why Adaptation and Mood Monitoring Matter
Why standard sleep restriction may need bipolar-specific adaptation, what pilot trials show, and which warning signs require prompt psychiatric review.
Evidence reviewed through: Aug 18, 2026 Sleep & CBT-ICBT-I for Chronic Pain: Sleep Benefits and Limits for Pain Relief
What CBT-I can improve when chronic pain and insomnia coexist, why sleep benefits are usually larger than pain benefits, and how treatment may be adapted.
Evidence reviewed through: Aug 18, 2026 Sleep & CBT-ICBT-I for COMISA: Treating Insomnia Alongside Sleep Apnea and PAP
How CBT-I and obstructive sleep apnea treatment work together, what trials show about sequencing and PAP adherence, and when sleep restriction needs caution.
Evidence reviewed through: Aug 18, 2026 Sleep & CBT-ICBT-I for Menopause, Hot Flashes, and Night Sweats
What CBT-I improves in menopause-related insomnia, why hot-flash frequency and interference are different outcomes, and what still needs parallel treatment.
Evidence reviewed through: Aug 19, 2026 Sleep & CBT-ICBT-I for Older Adults: Benefits, Access, and Fall-Risk Adaptations
Evidence for full, brief, telephone, and digital CBT-I in older adults, with adaptations for falls, sleepiness, cognition, nocturia, and polypharmacy.
Evidence reviewed through: Aug 18, 2026 Sleep & CBT-ICBT-I for PTSD and Nightmares: Where Imagery Rehearsal Therapy Fits
Evidence on CBT-I for insomnia in PTSD, the separate role of imagery rehearsal therapy for nightmares, sequencing limits, and trauma-informed adaptation.
Evidence reviewed through: Aug 18, 2026 Sleep & CBT-ICBT-I With Depression or Anxiety: What May Improve and What Still Needs Treatment
Evidence on CBT-I when insomnia occurs with depression or anxiety, including secondary mood benefits, limits, and warning signs that need separate care.
Evidence reviewed through: Aug 18, 2026 Sleep & CBT-ICBT-I: Components, Effectiveness, Safety, and What It Is Not
A complete evidence-based guide to CBT-I, including core components, expected benefits, safety adaptations, delivery formats, and limits.
Evidence reviewed through: Aug 19, 2026 Sleep & CBT-IDigital CBT-I vs Therapist-Led CBT-I: Effectiveness, Support, and How to Judge a Program
How validated digital CBT-I compares with therapist-led care, what evidence belongs to the exact program, and when stepped-up support is appropriate.
Evidence reviewed through: Aug 18, 2026Other Medications
19 articles
Gabapentin Withdrawal and Tapering: What Evidence and Safety Warnings Actually Say
Evidence-based answers about gabapentin dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsPregabalin (Lyrica) Withdrawal: Dependence, Symptoms, and Prescriber-Led Reduction
Evidence-based answers about pregabalin dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsPrescription Opioid Tapering: Why Rapid or Forced Reductions Can Cause Harm
A patient-centered explanation of prescription opioid tapering, the harms of abrupt or forced reductions, withdrawal and overdose risk, and what…
Evidence reviewed through: Aug 18, 2026 Other MedicationsADHD Medication Discontinuation: Rebound Symptoms vs Physiological Withdrawal
How to distinguish end-of-dose rebound, return of ADHD symptoms, and withdrawal after prolonged stimulant exposure, with separate considerations for…
Evidence reviewed through: Aug 18, 2026 Other MedicationsAntipsychotic Dose Reduction After Psychosis: What the RADAR Trial Changed
A plain-English review of the RADAR randomized trial, its finding of more relapse without better social functioning at two years, and what it does and…
Evidence reviewed through: Aug 18, 2026 Other MedicationsAripiprazole Reduction: Long Half-Life and Delayed Changes
Evidence-based answers about aripiprazole dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsBuprenorphine Tapering: Why Treatment Goals and Overdose Risk Must Come First
Evidence-based answers about buprenorphine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsLamotrigine Discontinuation: Indication, Seizure Risk, and Mood Relapse Questions
Evidence-based answers about lamotrigine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsLithium Discontinuation: Why Relapse Risk Matters More Than a Generic “Withdrawal Timeline”
Evidence-based answers about lithium dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsOlanzapine Reduction: Cholinergic Symptoms, Sleep, and Relapse Monitoring
Evidence-based answers about olanzapine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsQuetiapine (Seroquel) Reduction: Withdrawal Symptoms, Insomnia, and Relapse Risk
Evidence-based answers about quetiapine dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsTramadol Withdrawal: Opioid, Serotonergic, and Seizure Considerations
Evidence-based answers about tramadol dose reduction, possible withdrawal symptoms, timing, formulation issues, and when clinical assessment is urgent.
Evidence reviewed through: Aug 18, 2026 Other MedicationsAnticholinergic Deprescribing: Burden, Benefits, and Withdrawal-Like Symptoms
A specialist-review guide to reducing anticholinergic burden while separating potential cognitive and fall benefits from recurrence of the treated…
Evidence reviewed through: Aug 18, 2026 Other MedicationsAntiseizure Medication Withdrawal: Why the Diagnosis and Seizure Risk Come First
A specialist-review guide explaining why antiseizure medication withdrawal depends on the indication, epilepsy syndrome, seizure history,…
Evidence reviewed through: Aug 18, 2026 Other MedicationsBaclofen Withdrawal: Oral Symptoms and the Intrathecal Pump Emergency
A high-risk guide distinguishing oral baclofen withdrawal from intrathecal pump interruption, with emergency signs, device failure concerns, and…
Evidence reviewed through: Aug 18, 2026 Other MedicationsBeta-Blocker Discontinuation: Rebound Heart Rate, Blood Pressure, and Angina Risk
A high-risk guide to beta-blocker discontinuation, explaining why the indication, drug, dose, half-life, cardiac history, and rebound symptoms must be…
Evidence reviewed through: Aug 18, 2026 Other MedicationsClonidine Withdrawal: Rebound Hypertension and Sympathetic Symptoms
A high-risk guide to clonidine withdrawal and rebound hypertension, including missed-dose risk, formulation differences, interacting medications, and…
Evidence reviewed through: Aug 18, 2026 Other MedicationsCorticosteroid Tapering: Adrenal Suppression, Disease Flare, and Emergency Symptoms
A high-risk specialist guide to systemic corticosteroid tapering, distinguishing adrenal insufficiency, glucocorticoid withdrawal syndrome, and recurrence…
Evidence reviewed through: Aug 18, 2026 Other MedicationsProton-Pump Inhibitor Deprescribing: Rebound Acid Symptoms and Reasons Not to Stop
A specialist-review guide to proton-pump inhibitor deprescribing, rebound acid symptoms, indication review, step-down options, and conditions that may…
Evidence reviewed through: Aug 18, 2026Symptoms & Recovery
5 articles
Sleep During Medication Withdrawal: Rebound, Insomnia, CBT-I, and When to Slow Down
A corrected guide to sleep changes during withdrawal, CBT-I, class-specific taper responses, safety adaptation, and why fixed recovery timelines can mislead.
Evidence reviewed through: Aug 19, 2026 Symptoms & RecoveryAkathisia During Medication Reduction: How to Recognize It and When It Is Urgent
A safety-focused guide to inner restlessness during medication reduction, how akathisia differs from anxiety, and when severe distress needs urgent…
Evidence reviewed through: Aug 18, 2026 Symptoms & RecoveryPost-SSRI Sexual Symptoms After Discontinuation: Definitions, Evidence, and Uncertainty
A careful explanation of persistent sexual symptoms reported after SSRI or SNRI discontinuation, recognized warnings, major evidence gaps, and clinical…
Evidence reviewed through: Aug 18, 2026 Symptoms & RecoveryWhat Are Brain Zaps in Antidepressant Withdrawal?
Brain zaps are electric-shock sensations of antidepressant withdrawal, often triggered by eye movement. Not dangerous, but a sign your taper may be too fast.
Jul 2, 2026 Symptoms & RecoveryWindows and Waves: Why Withdrawal Recovery Isn't Linear
Windows are stretches of feeling normal; waves are returning symptoms. Recovery from medication withdrawal is non-linear — here's why, and how to cope.
Jul 2, 2026Practical Tapering Tools
7 articles
Alternate-Day Dosing: Why Skipping Days Can Make Withdrawal Harder
Why taking a medication every other day can create larger concentration swings, when exceptions exist, and how to ask for more consistent smaller-dose…
Evidence reviewed through: Aug 18, 2026 Practical Tapering ToolsHow to Make Smaller Medication Doses: Liquids, Compounding, Tablet Splitting, and Beads
A formulation-first guide to making smaller medication doses without assuming that every tablet can be split or every capsule can be opened.
Evidence reviewed through: Aug 18, 2026 Practical Tapering ToolsWhich Medication Should Be Reduced First? Principles for Multi-Drug Taper Planning
A structured way to discuss medication sequence in polypharmacy without pretending there is one universal order.
Evidence reviewed through: Aug 18, 2026 Practical Tapering ToolsMedication Reduction During Pregnancy or Breastfeeding: Why Risk–Benefit Review Is Essential
Why pregnancy and breastfeeding decisions must compare medication exposure with relapse, withdrawal, untreated illness, and infant or maternal risk—not…
Evidence reviewed through: Aug 18, 2026 Practical Tapering ToolsModified-Release, Enteric-Coated, and Delayed-Release Medicines: What Must Not Be Crushed or Opened
A product-specific guide to release systems, dose dumping, enteric protection, and how to find smaller-dose options without unsafe manipulation.
Evidence reviewed through: Aug 18, 2026 Practical Tapering ToolsTapering in Older Adults With Multiple Medications
A geriatric framework for reducing medications while protecting function, cognition, falls, disease control, and the person’s goals.
Evidence reviewed through: Aug 18, 2026 Practical Tapering ToolsHow to Talk to Your Doctor About Coming Off Medication
A calm, practical guide to raising deprescribing with your prescriber: what to prepare, exact scripts to use, the data that helps, and how to handle pushback.
Jul 2, 2026Research & Emerging Evidence
32 articles
Protracted Antidepressant Withdrawal: What the Evidence Shows—and What It Cannot Yet Tell Us
A balanced review of persistent symptoms after antidepressant reduction, the limits of current evidence, competing explanations, and appropriate clinical…
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceWhy Antidepressant Withdrawal Studies Disagree
Why antidepressant withdrawal estimates differ across randomized trials, meta-analyses, surveys, and long-term user studies—and how to read the numbers…
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceDORAs for Cancer-Related Insomnia: Early Evidence and Major Gaps
An evidence translation article on dual orexin receptor antagonists for cancer-related insomnia, separating general insomnia trials from limited…
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceAI Symptom Pattern Detection: Correlation, Confounding, and Safe Product Wording
How AI may organize symptom and dose timelines, why correlation is not diagnosis, and what safe product claims should say.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceAntipsychotic Hyperbolic Reduction: Receptor Theory vs Clinical Relapse Outcomes
How dopamine receptor-occupancy theory supports smaller reductions at low doses, and why clinical relapse evidence remains decisive.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceASAM 2025 vs the Ashton Manual: What Changed, What Stayed, and Where Evidence Is Limited
A respectful comparison of the 2025 multisociety benzodiazepine guideline and the Ashton Manual, including shared principles and key differences.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceBenzodiazepine Deprescribing in Older Adults: Digital Prompts, Pharmacist Interventions, and Shared Decisions
What deprescribing interventions in older adults teach about education, pharmacist review, clinician prompts, and shared decision-making.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceCBT-I and Behavioral Support During Hypnotic Deprescribing
What trials and guidelines show about CBT-I and behavioral support during benzodiazepine-receptor-agonist deprescribing.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceCBT-I With DORAs: What Is Known, What Has Not Been Tested, and How to Avoid Overclaiming
A research-focused review of combining CBT-I with dual orexin receptor antagonists, separating evidence for each treatment from the missing combination evidence.
Evidence reviewed through: Aug 19, 2026 Research & Emerging EvidenceDigital and Telephone Support for Antidepressant Discontinuation: Lessons From REDUCE
What the REDUCE cluster randomized trial teaches about scalable online and telephone support for people considering long-term antidepressant discontinuation.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceDirect Taper vs Long-Acting Substitution: Clinical Logic and Evidence Gaps
The pharmacologic logic for direct benzodiazepine tapering versus long-acting substitution, and why comparative evidence remains weak.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceDo DORAs Cause Withdrawal? What the FDA Labels Actually Tested
What DORA clinical trials and US labels mean when they report no clear withdrawal or rebound signal—and why those findings do not settle risk for every…
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceDoes Longer Antidepressant Use Increase Withdrawal Risk? What Observational Data Suggest
What observational evidence suggests about duration of antidepressant use and withdrawal severity, and why causal conclusions remain uncertain.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceDORAs and Sleep Apnea or COPD: What Respiratory Studies Can—and Cannot—Exclude
What short respiratory studies and DORA labels say about obstructive sleep apnea and COPD—and why they do not establish safety in severe or unstable disease.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceDORAs in 2026: How Quviviq, Dayvigo, and Belsomra Differ
A 2026 evidence-based comparison of daridorexant, lemborexant, and suvorexant, using generic names consistently and separating label facts from indirect…
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceDORAs in Older Adults: Sleep Benefits, Falls, Driving, and Next-Day Function
How to interpret DORA trials in older adults, including sleep outcomes, next-day function, falls, cognition, and the limits of short studies.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceFormulation Accuracy at Tiny Doses: What the 2025 Systematic Review Found
What the 2025 systematic review found about manipulating dosage forms for psychotropic tapering—and why many popular methods remain insufficiently validated.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceHow Withdrawal Is Measured: DESS, Symptom Checklists, Function, and Patient-Reported Outcomes
How withdrawal scales work, what they miss, and why symptom count, severity, timing, function, and relapse all need separate measurement.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceHyperbolic Tapering: Strong Pharmacologic Rationale, Limited Comparative Outcome Evidence
Why nonlinear dose–occupancy relationships support smaller reductions at low doses, while comparative clinical evidence remains incomplete.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceOne Drug at a Time: Evidence and Logic in Polypharmacy Deprescribing
Why changing one medication at a time often improves causal interpretation, when simultaneous changes are necessary, and where direct evidence is limited.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceOrexin Drugs Beyond Insomnia: Depression, Addiction, and the Limits of Early Evidence
A nonpromotional overview of orexin-targeting research in depression, addiction, and other psychiatric conditions, emphasizing early-stage limits.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidencePersistent or Protracted Withdrawal: Why the Evidence Base Is Still Sparse
Why persistent withdrawal remains difficult to quantify, what types of evidence exist, and how future research can avoid dismissing or overclaiming.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceSeltorexant and Selective OX2 Antagonism: A New Direction for Depression With Insomnia?
What selective orexin-2 receptor antagonism is intended to do, what seltorexant trials have studied, and why the medication remains investigational.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceSlow Tapering Plus Psychological Support: What the 2026 Network Meta-Analysis Found
A method-focused review of the 2026 network meta-analysis comparing antidepressant deprescribing strategies, including certainty and outcome limits.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceSwitching From Benzodiazepines or Z-Drugs to a DORA: Evidence, Risks, and Open Questions
Why switching from a benzodiazepine or Z-drug to a DORA is not a simple dose conversion, and what evidence and safety questions remain.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceVornorexant: The New DORA Approved in Japan in 2025
What is known about vornorexant after its 2025 approval in Japan, including its phase 3 evidence, rapid-on/rapid-off concept, and regional limits.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceWearables During Tapering: Useful Trends, but Not a Diagnostic Tool
How sleep and activity wearables can support trend tracking during medication changes without diagnosing withdrawal, relapse, or sleep disorders.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceWhat the RADAR Trial Means for Antipsychotic Dose Reduction
A deeper methods review of RADAR: population, intervention, outcomes, relapse findings, follow-up, and responsible clinical interpretation.
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceWhy 2024 and 2025 Antidepressant Withdrawal Meta-Analyses Look Reassuring—Yet Do Not End the Debate
A side-by-side interpretation of the 2024 Lancet Psychiatry and 2025 JAMA Psychiatry meta-analyses, including why their averages do not settle long-term…
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceWhy a “5–10%” Starting Reduction Is Not a Universal Schedule
What the 2025 benzodiazepine guideline means by a cautious starting range—and why it must not be converted into a rigid monthly algorithm.
Evidence reviewed through: Aug 19, 2026 Research & Emerging EvidenceWhy SSRI Receptor-Occupancy Logic Cannot Be Copied Unchanged to Every Psychiatric Drug
Why transporter or receptor occupancy is target-, drug-, and outcome-specific, and cannot supply one taper curve for antidepressants, antipsychotics,…
Evidence reviewed through: Aug 18, 2026 Research & Emerging EvidenceReceptor Occupancy: Why the Last Milligrams Are Hardest
Receptor occupancy explains why the last milligrams of an SSRI taper are the hardest: the serotonin transporter saturates fast, so tiny doses still block a lot.
Jul 2, 2026